A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome
Latest Information Update: 23 Sep 2024
At a glance
- Drugs HRS 9531 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Fujian Shengdi Pharmaceutical
- 23 Sep 2024 New trial record